In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study.

Trial Profile

In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Tofacitinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RAXEL
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 18 May 2017 to 18 May 2019.
    • 14 May 2016 Planned End Date changed from 18 Jun 2015 to 18 May 2017.
    • 13 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top